Researchers found that only about one-third of patients with poorly
controlled blood sugar on oral drugs were switched to higher doses,
different drugs or insulin within six months.
At the start of the study, all of the patients had been taking two
oral diabetes drugs for at least six months. But they still had
poorly controlled diabetes based on blood tests showing so-called
hemoglobin A1c levels, which reflect average blood sugar levels over
about three months. Readings above 6.5 signal diabetes, and everyone
in the study had readings of at least 7.
Under U.S. guidelines for managing diabetes, all such patients
should be switched to more intense treatment, researchers note in
Diabetes Care.
But six months after the start of the study, doctors had only
prescribed more intense therapy for 37 percent of these patients.
"Generally speaking, if a patient's A1c is above target, it will
either remain there or get worse," said lead study author Dr. Kevin
Pantalone of the Cleveland Clinic in Ohio. "It does not usually get
better."
Globally, about one in 10 adults has diabetes, according to the
World Health Organization. Most have type 2 diabetes, which is
associated with obesity and aging and occurs when the body can't
make or process enough of the hormone insulin.
Medications as well as lifestyle changes such as improved diet and
exercise habits can help manage diabetes and keep symptoms in check.
When diabetes isn't well managed, however, dangerously high blood
sugar can eventually lead to blindness, amputations, kidney failure,
heart disease and stroke.
Too often, doctors and patients will find reasons not to intensify
treatment, making these complications more likely, Pantalone said by
email.
"Whether it be the patient saying for the fifth time 'I will start
watching my diet and start exercising,' or a physician saying 'the
A1c is close to goal and I don't really want to add yet another
medication and copay, we will wait and see what happens in another 3
months,' the end result is lack of intensification and A1c goal
attainment," Pantalone said.
[to top of second column]
|
In the current study, researchers examined electronic health records
for 7,389 patients with poorly controlled diabetes who were treated
at the Cleveland Clinic between 2005 and 2016.
People with the most poorly controlled blood sugar were more likely
to get more intense treatment, the study found.
Among patients with A1c readings from 7 to 7.9, just 28 percent of
patients were switched to more intense treatment during the study.
However, about 47 percent of patients with A1c readings from 8 to
8.9 were switched, as were almost 60 percent of patients with A1c
readings of 9 or higher.
The study wasn't a controlled experiment designed to prove whether
or how treatment intensification might directly improve blood sugar.
Researchers also lacked data to explain why doctors or patients
might have decided against a change in therapy. And the study didn't
show whether failure to switch treatment regimens resulted in
diabetes complications.
Still, such complications can become more likely the longer patients
go with poorly controlled blood sugar, said Dr. Vanessa Arguello of
the David Geffen School of Medicine at the University of California,
Los Angeles.
"When appropriate, patients need to be involved in escalating their
diabetes care to prevent diabetic complications and stay healthy,"
Arguello, who wasn't involved in the study, said by email.
"Patients should empower themselves by checking their blood sugars
daily, knowing what their target blood sugar levels should be, and
having regular appointments with their doctor," Arguello added. "If
patients are having blood sugars above their target blood sugar
levels then this may be a warning sign that they need to talk with
their physician on how to take a different approach in managing
their diabetes."
SOURCE: http://bit.ly/2rI8HUu Diabetes Care, online April 20, 2018.
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |